INSMED IncINSMEarnings & Financial Report
Insmed Inc. is a global biopharmaceutical firm focused on developing and commercializing innovative therapies for patients with serious rare diseases that have high unmet medical needs. Its key offerings target pulmonary and endocrine rare disorders, serving markets across North America, Europe, and Asia Pacific.
Revenue
$107.4M
Gross Profit
$79.3M
Operating Profit
$-312.9M
Net Profit
$-321.7M
Gross Margin
73.9%
Operating Margin
-291.3%
Net Margin
-299.5%
YoY Growth
18.9%
EPS
$-1.70
INSMED Inc Q2 FY2025 Financial Summary
INSMED Inc reported revenue of $107.4M (up 18.9% YoY) for Q2 FY2025, with a net profit of $-321.7M (down 7.0% YoY) (-299.5% margin). Cost of goods sold was $28.1M, operating expenses totaled $392.2M.
Key Financial Metrics
| Total Revenue | $107.4M |
|---|---|
| Net Profit | $-321.7M |
| Gross Margin | 73.9% |
| Operating Margin | -291.3% |
| Report Period | Q2 FY2025 |
INSMED Inc Annual Revenue by Year
INSMED Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $606.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $606.4M |
| 2024 | $363.7M |
| 2023 | $305.2M |
| 2022 | $245.4M |
INSMED Inc Quarterly Revenue & Net Profit History
INSMED Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $263.8M | +152.6% | $-328.5M | -124.5% |
| Q3 FY2025 | $142.3M | +52.4% | $-370.0M | -260.0% |
| Q2 FY2025 | $107.4M | +18.9% | $-321.7M | -299.5% |
| Q1 FY2025 | $92.8M | +22.9% | $-256.6M | -276.4% |
| Q4 FY2024 | $104.4M | +24.8% | $-235.5M | -225.5% |
| Q3 FY2024 | $93.4M | +18.2% | $-220.5M | -236.0% |
| Q2 FY2024 | $90.3M | +17.0% | $-300.6M | -332.8% |
| Q1 FY2024 | $75.5M | +15.8% | $-157.1M | -208.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.5M | $90.3M | $93.4M | $104.4M | $92.8M | $107.4M | $142.3M | $263.8M |
| YoY Growth | 15.8% | 17.0% | 18.2% | 24.8% | 22.9% | 18.9% | 52.4% | 152.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.16B | $1.81B | $2.05B | $2.03B | $1.80B | $2.48B | $2.36B | $2.26B |
| Liabilities | $1.62B | $1.77B | $1.57B | $1.74B | $1.70B | $1.23B | $1.42B | $1.53B |
| Equity | $-464.8M | $38.8M | $483.4M | $285.4M | $99.2M | $1.25B | $945.6M | $739.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-184.0M | $-123.0M | $-180.9M | $-196.0M | $-262.1M | $-205.6M | $-219.8M | $-247.6M |